The global seasonal allergy market enjoys a valuation of USD 1.15 Billion in 2022, and it is further projected to expand at a CAGR of 7.8% over the forecasted years. According to a recent study by Future Market Insights, tablets/capsules by form leading the market with a share of about 37.1% in the year 2022, within the global market.
Market Outlook
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | USD 1.15 Billion |
| Market Value 2023 | USD 1.22 Billion |
| Market Value 2033 | USD 2.58 Billion |
| CAGR 2023 to 2033 | 7.8% |
| Market Share of Top 5 Countries | 62.1% |
| Key Market Players | Merck KGaA, Johnson & Johnson, Allergopharma, Sanofi SA, McNeil Consumer Healthcare, Genentech Inc., GlaxoSmithKline PLC, Leti Pharma, Alerpharma S.A, Allergan, Inc., Meda Pharmaceuticals, Inc, Novartis International AG, Bausch Health Companies Inc., Allergopharma, ALK Abello, Stallergenes, Greer, Allergy Therapeutics, Aimmune Therapeutics, Biomay AG, HAL Allergy Group, Bayer, AstraZeneca |
Seasonal allergies, like other allergies, develop when the body's immune system overreacts to a trigger in the environment, usually in the spring, summer, or fall when specific plants pollinate. A growing number of producers have identified allergies as a viable market, and with the help of a research and development team, they are delivering fresh, cutting-edge therapy and treatment options to the market, expanding the range of already available treatments. A large portion of people are still affected by seasonal allergies yearly.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The global sales of the market are anticipated to rise at a CAGR of 7.8% between 2023 and 2033, owing to the rising prevalence of allergic diseases.
The global market holds around 5.7%share of the overall global allergy treatment market with a value of around USD 20.2 Million, in 2022.
Longer pollen seasons during warmer temperatures or higher carbon dioxide emissions brings about higher quantities of pollen. These are the key contributors to the seasonal allergies affecting an individual. The incidence rate and prevalence rate of seasonal allergies are growing rapidly owing to which the demand for available treatments is expected to increase over the forecast period.
Antihistamines, decongestants, nasal corticosteroids, allergen immunotherapy, and leukotriene receptor antagonists are some of the most well-liked treatments for seasonal allergies. Antihistamines dominate the market since they are one of the most widely used and widely prescribed medications for the treatment of allergies, both with and without a prescription.
Owing to the above-mentioned factors, the global market is expected to grow at a prominent pace, and reach a valuation of around USD 2.58 Billion during the year 2033.
This creates an enormous opportunity for the manufacturer to explore the seasonal allergy market. Several biopharma businesses with tested technology and cutting-edge treatment choices that are unique and have been approved have emerged as a result of the life science industry's entry into the pharmaceutical sector. This enables medical professionals to rely on these novel treatment possibilities.
For instance, allergy immunotherapy as a treatment has proven to be successful in multiple clinical trials. Such as high-dose, standardized vaccinations are used in subcutaneous injection immunotherapy (SCIT). These medications typically contain 5–20 mcg of the main allergen. SCITs are given as maintenance injections every month. Also, sublingual allergy immunotherapy (SLIT) involves the sublingual space's unique, tolerance-promoting immune cells, also known as oral Langerhans cells. Liquid antigens (drops) and pills are the two therapeutic options for SLIT.
Overall, it is anticipated that the market for seasonal allergies will rise over the coming years as more research and development are put into creating fresh, efficient treatment choices.
The market is experiencing a decline due to the adverse effects associated with allergy shots and tablets.
Periodic injections are administered over time as allergy shots. Immunotherapy for allergies is a protracted treatment that might last anywhere between three and five years. It entirely depends on the kind and degree of allergy.
Each allergy shot contains a very small amount of the exact ingredients or substances that cause allergic responses.
Patients frequently discontinue therapy in the middle of the procedure due to extended treatment schedules, age, health, physical location, and financial constraints.
The time associated with the treatment may hinder market growth.
The USA dominates the North American region with a global market share of around 30.8% in 2022. In the United States, the importance of artificial intelligence (AI) in medical sciences cannot be overstated. The healthcare industry in the US is one of the largest in the world, and it faces numerous challenges, such as rising costs, an aging population, and a shortage of healthcare professionals.
AI has the potential to address many of these challenges by improving the accuracy and efficiency of medical diagnosis and treatment. For instance, in the case of seasonal allergies, AI The Weather Channel data science team has been trying to develop a tool to assist seasonal allergy sufferers as spring progresses and summer draws closer. Allergy Insights with Watson, a new service that uses AI to assist forecast seasonal allergy risk in the United States, is freely accessible on The Weather Channel app and weather.com.
In order to aware people in making the more appropriate decisions and preparing for allergy season, united states in going to witness an exponential growth in the global market
China has a market share of 9.5%, with a market value of USD 109.9 Million in the global seasonal allergy market in 2022.
In China, allergy immunotherapy (AIT) has been practiced for more than 60 years. The Chinese College of Allergy and Asthma (CCAA), a specialized branch of CDMA that serves as the primary certifying body for AIT, was formed in 2016 with the backing of the Chinese Medical Association (CMA) and the Chinese Medical Doctors Association (CMDA). Chinese allergists and researchers have made significant advancements in the creation of AIT. Chinese allergists and researchers have published a large number of articles globally that include original research investigations, systematic reviews, case studies, and clinical trials. Sublingual immunotherapy (SLIT) is starting to gain popularity in China, where traditional subcutaneous immunotherapy (SCIT) is now the favored AIT.
Similar to the United States, immunotherapy is popular in China and it is expected to establish a steady growth in the coming years.
Germany holds a market share of 8.7% in 2022 in the global seasonal allergy market, owing to the presence of many established players in European countries.
Germany is a global leader in biotechnology, and the environment for the growth of commercial biotechnology is only improving. This has a favorable impact on the growth of new businesses that specialize in this industry. There were more businesses between 2015 and 2019 by 20.7%. Germany continues to be the top European nation for funding the biotechnology sector. 78% of the industry's overall budget in 2019 was generated through venture capital and initial public offerings (IPOs). About 70% of all businesses in Germany use biotechnology for medical purposes, which is particularly significant in light of the recent developments brought on by COVID-19.
Germany is strengthening its manufacturing and development of novel drugs which will positively grow the market in the future.
India holds a share of around 6.6% in the global market in 2022.
The prevalence of allergies and asthma is increasing in India, and it has turned into a serious health issue. Symptoms can range from mild rhinitis to severe asthma, and even life-threatening anaphylaxis. This subcontinent has a very broad "allergen repertoire" because of its distinct climatic conditions, flora, and dietary customs. To make an accurate diagnosis and create immunotherapeutic vaccines, allergy-eliciting chemicals must be correctly identified, purified, and molecularly characterized. Although there are many reports on common allergies, the majority of these studies relied on early allergen detection and identification. Recombinant technologies and structural biology have only been used to characterize a small number of these allergen compounds.
There are still millions of cases of the disease worldwide, despite India's prevalence rates generally being lower than those of high-income countries. Due to the large number of patients, Indian biopharmaceutical companies must enhance their supply of treatment medications.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Tablets/Capsules are mostly favored by patients suffering from allergies. It has contributed USD 427.4 Million to the global market in 2022.
Because of its durability and patient acceptability, the tablet is the most commonly utilized dosage form out of all those that are available. As a result, the coating plays a crucial role in the tablet's composition. The superior aesthetic qualities, such as color, texture, mouth feel, and flavor masking, depending on the film and sugar coatings. This makes tablets/capsules the most lucrative form.
OTC led the global market with over 76.0% value share in 2022. Customers find it simpler to buy OTC medications because they are widely accessible and may be purchased without a prescription. People can save time and money by not having to wait for prescriptions to be filled or make appointments with doctors. More people can afford OTC medications because they are often less expensive than prescription medicines.
Oral is mostly preferred by patients. It has a market share of 36.6% in the global market in 2022. Oral drugs are uncomplicated to administer, patients can take them at home without a doctor's supervision. Oral drugs are advantageous for those with chronic illnesses who require long-term care. Oral drugs are typically less expensive than those administered intravenously or orally, which necessitate more specialized equipment and physician oversight.
Antihistamines have a market share of 46.0% in the global market in 2022.
The ease of use and accessibility of over-the-counter antihistamines is high. Second-generation antihistamines are also thought to be a better option. However, each one must be assessed based on their particular efficacy and safety.
Hospital pharmacies hold a market share of 35.9% during the year 2022. Hospitals are the primary locations where readily available, licensed, and approved medication can be found. By collaborating with doctors, nurses, and pharmacy staff to provide the proper medications and supplies during treatment procedures, hospital pharmacies can significantly improve patient care. Hospitals can exceed their patient satisfaction goals with the guarantee of improved patient outcomes. Due to the extensive treatment offered in hospital settings, the category is predicted to expand at a profitable rate throughout the projection period.
Collaboration with scientific and research foundations to increase public awareness and receiving product approvals from regulatory bodies are the key strategies opted by key players within this market space.
Similarly, recent developments related to companies within the seasonal allergy market space have been tracked by the team at Future Market Insights. These are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2018 to 2022 |
| Historical Data Available for | 2023 to 2033 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; and the Middle East & Africa |
| Key Countries Covered | The USA, Canada, Brazil, Mexico, Argentina, the United kingdom, Germany, Italy, Russia, Spain, France, Benelux, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Türkiye, GCC Countries, North Africa and South Africa |
| Key Market Segments Covered | Form, Prescription Type, Route of Administration, Treatment, Distribution Channel |
| Key Companies Profiled | Merck KGaA; Johnson & Johnson; Allergopharma; Sanofi SA; McNeil Consumer Healthcare,; Genentech Inc.; GlaxoSmithKline PLC; Leti Pharma,; Alerpharma S.A; Allergan, Inc.; Meda Pharmaceuticals, Inc; Novartis International AG; Bausch Health Companies Inc.; Allergopharma; ALK Abello; Stallergenes Greer; Allergy Therapeutics; Aimmune Therapeutics; Biomay AG; HAL Allergy Group; Bayer; AstraZeneca |
| Pricing | Available upon Request |
The seasonal allergy market is anticipated to go up from USD 1.22 billion in 2023 to USD 2.58 billion by 2033, exhibiting a CAGR of 7.8%.
With a 5.7% CAGR between 2018 and 2022, the seasonal allergy market size reached USD 1.15 billion in 2022.
Given its prevalent allergenic flora and demand for effective treatments, the United States stands as the dominant market for seasonal allergy products.
Seasonal allergy market trends include rising allergen sensitization, personalized treatment demand, and improved allergy management methods.
Prominent market players such as Merck KGaA, Johnson & Johnson, Allergopharma, Sanofi SA, McNeil Consumer Healthcare, and Genentech Inc. dominate the seasonal allergy market.
| Estimated Market Size (2024E) | USD 6220 million |
|---|---|
| Projected Market Value (2034F) | USD 13060.1 million |
| Value-based CAGR (2024 to 2034) | 7.7% |
| Market Value (2023) | USD 1.74 billion |
|---|---|
| Market Expected Value (2033) | USD 4.07 billion |
| Market Projected CAGR (2023 to 2033) | 8.9% |
| Expected Market Value (2023) | USD 571 Million |
|---|---|
| Anticipated Forecast Value (2033) | USD 1123.24 Million |
| Projected Growth Rate (2023 to 2033) | 7% CAGR |
| Expected Market Value (2023) | USD 5850.8 Million |
|---|---|
| Projected Forecast Value (2033) | USD 8828.6 Million |
| Growth Rate (2023 to 2033) | 4.2% CAGR |
Explore Therapy Area Insights
View Reports
Seasonal Allergy Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
